<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01503892</url>
  </required_header>
  <id_info>
    <org_study_id>StLukeHHN</org_study_id>
    <nct_id>NCT01503892</nct_id>
  </id_info>
  <brief_title>Metanx Effects on Nerve Fiber Density in Neuropathic Diabetics</brief_title>
  <acronym>SLHN2011-18</acronym>
  <official_title>Metanx Effects on Nerve Fiber Density in Neuropathic Diabetics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Luke's Hospital and Health Network, Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Goldfarb Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pamlab, L.L.C.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Luke's Hospital and Health Network, Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study focuses on the use of Metanx速 as the sole treatment for improving and reversing
      nerve damage in type 2 diabetic patients with peripheral neuropathy. There will be two equal
      study groups enrolled in this randomized double blinded study. The minimum sample size of
      enrollment is 24 (12 per group), which is required for 90% power at alpha = .05. The maximum
      number of participants will be set at 100 (50 per group). Patients who are pre-diabetic or
      patients who have been diagnosed with diabetes type II for less than five years are included
      in this study. The control group will receive placebo pill twice daily versus the treatment
      group which will receive one Metanx速 tablet twice daily. Each group will have intraepidermal
      nerve fiber densities obtained by skin biopsies taken at the beginning of the study before
      any treatment has begun as well as a final intraepidermal nerve skin biopsy at the end of
      twelve months to re-biopsy. In addition each group will answer three sets of questionnaires
      relating to their peripheral neuropathy at initial, three months, twelve month visitations.
      If Metanx速 is able to reverse nerve damage and improve symptoms then the final nerve biopsies
      will show an increase in intraepidermal nerve fiber density and an improvement in the
      subjective score versus the placebo group.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2011</start_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increased intraepidermal nerve fiber density</measure>
    <time_frame>1 year</time_frame>
    <description>If Metanx速 is able to reverse nerve damage and improve symptoms then the final nerve biopsies will show an increase in intraepidermal nerve fiber density</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjective improvement</measure>
    <time_frame>1 year</time_frame>
    <description>Improvement in the subjective score versus the placebo group.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Diabetes</condition>
  <condition>Peripheral Neuropathy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The control group will receive placebo pill twice daily for twelve months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metanx</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metanx group will receive one pill twice daily for twelve months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Metanx</intervention_name>
    <description>Metanx- one tablet twice daily for twelve months</description>
    <arm_group_label>Metanx</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo- one tablet twice daily for twelve months.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 Diabetics

          -  Pre-diabetics

          -  Symptoms of peripheral neuropathy

        Exclusion Criteria:

          -  Pregnancy

          -  Under age 18

          -  HIV (+)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edwin S. Hart III, DPM</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Luke's Hospital and Health Network</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Edwin S. Hart III, DPM</last_name>
    <phone>610-868-4300</phone>
    <email>ehart@footmed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Luke's Hospital and Health Network</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edwin S. Hart III, DPM</last_name>
      <phone>610-868-4300</phone>
      <email>ehart@footmed.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.goldfarbfoundation.org/</url>
    <description>William L. Goldfarb Educational Foundation for Research and Teaching of the Lower Extremity</description>
  </link>
  <link>
    <url>http://www.pamlab.com</url>
    <description>PamLab</description>
  </link>
  <link>
    <url>http://www.mystlukesonline.org</url>
    <description>St. Luke's Hospital and Health Network</description>
  </link>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 29, 2011</study_first_submitted>
  <study_first_submitted_qc>December 31, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2012</study_first_posted>
  <last_update_submitted>July 16, 2012</last_update_submitted>
  <last_update_submitted_qc>July 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Luke's Hospital and Health Network, Pennsylvania</investigator_affiliation>
    <investigator_full_name>Edwin S. Hart III</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Small Fiber Neuropathy</keyword>
  <keyword>Metanx Effect on Small Fiber Neuropathy</keyword>
  <keyword>Metanx Effect on Diabetic Peripheral Neuropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin B 12</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

